Skip to main content

15.04.2024 | Case Report

Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review

verfasst von: Wataru Kitamura, Hiroki Kobayashi, Minori Noda, Akiko Iseki, Yumi Sato, Yoshinobu Maeda, Shoichi Kuyama

Erschienen in: International Journal of Hematology

Einloggen, um Zugang zu erhalten

Abstract

We report a rare case of spontaneous regression (SR) in an elderly untreated patient with multiple solitary plasmacytoma (MSP). Diagnosis of MSP was confirmed through surgical resection of the left nasal cavity mass and subsequent biopsy of the right humerus. The patient was considered ineligible for chemotherapy due to poor performance status. At 3-month post-diagnosis, the patient’s condition worsened with deteriorating bone lesions and emergence of a new serum monoclonal protein. However, these clinical findings completely disappeared at 6 months, and positron emission tomography–computed tomography at 1 year confirmed complete metabolic remission. Notably, peripheral blood lymphocyte counts were inversely correlated with tumor progression and remission. Pathological re-evaluation of the initial biopsy specimens revealed programmed cell death protein 1 (PD-1) expression in tumor-infiltrating CD8+ T cells. In addition, tumor cells were infected with Epstein–Barr virus (EBV) but were negative for programmed cell death ligand 1 (PD-L1) expression, which is the most potent immune escape mechanism in tumor cells. While the mechanism underlying SR remains unclear, our findings suggest that host immune response as well as EBV infection may contribute to SR. Further studies are needed to elucidate the clinicopathologic mechanisms of tumor regression in plasma cell neoplasms.
Literatur
1.
Zurück zum Zitat Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef Group IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57.CrossRef
2.
Zurück zum Zitat Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed
3.
Zurück zum Zitat Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.CrossRefPubMedPubMedCentral Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;101:794–808.CrossRefPubMed Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;101:794–808.CrossRefPubMed
5.
Zurück zum Zitat Zhang Y, Qi J, Qiu L. Multiple solitary plasmacytoma: characteristics, response to therapy, survival in nine patients from a single institute. Blood. 2013;122:5383.CrossRef Zhang Y, Qi J, Qiu L. Multiple solitary plasmacytoma: characteristics, response to therapy, survival in nine patients from a single institute. Blood. 2013;122:5383.CrossRef
6.
Zurück zum Zitat Yang B, Wang J, Cai LL, Zhu HL, Yu RL, Chi XH, et al. Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells. Cytotherapy. 2014;16:278–84.CrossRefPubMed Yang B, Wang J, Cai LL, Zhu HL, Yu RL, Chi XH, et al. Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells. Cytotherapy. 2014;16:278–84.CrossRefPubMed
7.
Zurück zum Zitat Cafferata MA, Chiaramondia M, Monetti F, Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer. 2004;45:263–6.CrossRefPubMed Cafferata MA, Chiaramondia M, Monetti F, Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer. 2004;45:263–6.CrossRefPubMed
8.
Zurück zum Zitat Wiernik PH. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976;44:35–8.PubMed Wiernik PH. Spontaneous regression of hematologic cancers. Natl Cancer Inst Monogr. 1976;44:35–8.PubMed
9.
Zurück zum Zitat Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Cancer. 1980;45:2627–32.CrossRefPubMed Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Cancer. 1980;45:2627–32.CrossRefPubMed
10.
Zurück zum Zitat Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Am J Hematol. 1989;31:138–41.CrossRefPubMed Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin’s lymphoma clinical and pathogenetic considerations. Am J Hematol. 1989;31:138–41.CrossRefPubMed
12.
Zurück zum Zitat Arunabh, Dutta Gupta S, Bal S, Sarda A, Vijayraghavan M, Shukla N, et al. Spontaneous regression of extramedullary plasmacytoma -a case report. Jpn J Surg. 1988;18:455–9.CrossRefPubMed Arunabh, Dutta Gupta S, Bal S, Sarda A, Vijayraghavan M, Shukla N, et al. Spontaneous regression of extramedullary plasmacytoma -a case report. Jpn J Surg. 1988;18:455–9.CrossRefPubMed
13.
Zurück zum Zitat Meziane M, Boulaadas M, Essakalli L, Kzadri M, Harmouch A. Solitary plasmocytoma: ghost tumour? Int J Oral Maxillofac Surg. 2012;41:17–9.CrossRefPubMed Meziane M, Boulaadas M, Essakalli L, Kzadri M, Harmouch A. Solitary plasmocytoma: ghost tumour? Int J Oral Maxillofac Surg. 2012;41:17–9.CrossRefPubMed
14.
Zurück zum Zitat Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Onco. 1982;5:649–55.CrossRef Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Onco. 1982;5:649–55.CrossRef
15.
Zurück zum Zitat Abe R, Ogawa K, Maruyama Y, Nakamura N, Abe M. Spontaneous regression of diffuse large b-cell lymphoma harbouring epstein-barr virus a case report and review of the literature. J Clin Exp Hematop. 2007;47:23–6.CrossRefPubMed Abe R, Ogawa K, Maruyama Y, Nakamura N, Abe M. Spontaneous regression of diffuse large b-cell lymphoma harbouring epstein-barr virus a case report and review of the literature. J Clin Exp Hematop. 2007;47:23–6.CrossRefPubMed
16.
Zurück zum Zitat Tanaka Y, Ishihara M, Miyoshi H, Hashimoto A, Shinzato I, Ohshima K. Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy. J Clin Exp Hematop. 2019;59:17–21.CrossRefPubMedPubMedCentral Tanaka Y, Ishihara M, Miyoshi H, Hashimoto A, Shinzato I, Ohshima K. Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy. J Clin Exp Hematop. 2019;59:17–21.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Krikorian JG, Portlock CS, Cooney P. Spontaneous regression of non-Hodgkin’s lymphoma a report of nine case. Cancer. 1980;46:2093–9.CrossRefPubMed Krikorian JG, Portlock CS, Cooney P. Spontaneous regression of non-Hodgkin’s lymphoma a report of nine case. Cancer. 1980;46:2093–9.CrossRefPubMed
18.
Zurück zum Zitat Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;11:1471–5.CrossRef Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;11:1471–5.CrossRef
19.
Zurück zum Zitat Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, et al. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009;27:e194–7.CrossRefPubMed Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, et al. Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol. 2009;27:e194–7.CrossRefPubMed
21.
Zurück zum Zitat Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.CrossRefPubMed
22.
Zurück zum Zitat Gion Y, Iwaki N, Takata K, Takeuchi M, Nishida K, Orita Y, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108:1271–80.CrossRefPubMedPubMedCentral Gion Y, Iwaki N, Takata K, Takeuchi M, Nishida K, Orita Y, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017;108:1271–80.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84.CrossRefPubMed Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84.CrossRefPubMed
24.
Zurück zum Zitat Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Kim IS, et al. Primary pulmonary plasmacytoma presenting as multiple lung nodules. Korean J Intern Med. 2012;27:111–3.CrossRefPubMedPubMedCentral Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Kim IS, et al. Primary pulmonary plasmacytoma presenting as multiple lung nodules. Korean J Intern Med. 2012;27:111–3.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis a case report and review of literature. Int J Clin Exp. 2015;8:2090–102. Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis a case report and review of literature. Int J Clin Exp. 2015;8:2090–102.
26.
Zurück zum Zitat Tokunaga T, Hashimoto H, Yoshida Y, Sugimoto T, Mokuda S, Kosaka Y, et al. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. Mod Rheumatol Case Rep. 2021;5:22–8.CrossRefPubMed Tokunaga T, Hashimoto H, Yoshida Y, Sugimoto T, Mokuda S, Kosaka Y, et al. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. Mod Rheumatol Case Rep. 2021;5:22–8.CrossRefPubMed
27.
Zurück zum Zitat Zhou T, Cheng J, Karrs J, Davies-Hill T, Pack SD, Xi L, et al. Clinicopathologic and molecular characterization of epstein-barr virus-positive plasmacytoma. Am J Surg Pathol. 2022;46:1364–79.CrossRefPubMed Zhou T, Cheng J, Karrs J, Davies-Hill T, Pack SD, Xi L, et al. Clinicopathologic and molecular characterization of epstein-barr virus-positive plasmacytoma. Am J Surg Pathol. 2022;46:1364–79.CrossRefPubMed
28.
Zurück zum Zitat Ohgaki F, Takemoto Y, Paku S, Tatezuki J, Kumagai J, Shuto T, et al. Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: a case report and literature review. Neuropathology. 2023;43:151–7.CrossRefPubMed Ohgaki F, Takemoto Y, Paku S, Tatezuki J, Kumagai J, Shuto T, et al. Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: a case report and literature review. Neuropathology. 2023;43:151–7.CrossRefPubMed
29.
Zurück zum Zitat Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56:940–6.CrossRefPubMed Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017;56:940–6.CrossRefPubMed
30.
Zurück zum Zitat Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients A systematic review of the literature. Joint Bone Spine. 2018;85:35–40.CrossRefPubMed Berti A, Felicetti M, Peccatori S, Bortolotti R, Guella A, Vivaldi P, et al. EBV-induced lymphoproliferative disorders in rheumatic patients A systematic review of the literature. Joint Bone Spine. 2018;85:35–40.CrossRefPubMed
31.
Zurück zum Zitat Tokuhira M, Tanaka Y, Takahashi Y, Kimura Y, Tomikawa T, Anan T, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. J Clin Exp Hematop. 2020;60:41–50.CrossRefPubMedPubMedCentral Tokuhira M, Tanaka Y, Takahashi Y, Kimura Y, Tomikawa T, Anan T, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders. J Clin Exp Hematop. 2020;60:41–50.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, et al. Restoration of decreased T Helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.CrossRefPubMedPubMedCentral Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, et al. Restoration of decreased T Helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018;9:621.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41:352–7.CrossRefPubMed Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41:352–7.CrossRefPubMed
34.
Zurück zum Zitat Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26:548–55.CrossRefPubMed Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26:548–55.CrossRefPubMed
35.
Zurück zum Zitat Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27:59–73.CrossRefPubMed Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27:59–73.CrossRefPubMed
36.
Zurück zum Zitat Tokuhira M, Kimura Y, Takahashi Y, Tomikawa T, Sagawa M, Anan T, et al. Impact Of Epstein-Barr viral infection in the regression of methotrexate-induced lymphoproliferative diseases in patients with rheumatoid arthritis. Blood. 2013;122:3006.CrossRef Tokuhira M, Kimura Y, Takahashi Y, Tomikawa T, Sagawa M, Anan T, et al. Impact Of Epstein-Barr viral infection in the regression of methotrexate-induced lymphoproliferative diseases in patients with rheumatoid arthritis. Blood. 2013;122:3006.CrossRef
37.
Zurück zum Zitat Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.CrossRefPubMed Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.CrossRefPubMed
38.
Zurück zum Zitat Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016;4:779–88.CrossRefPubMed Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016;4:779–88.CrossRefPubMed
39.
Zurück zum Zitat Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ, et al. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep. 2020;10:12641.CrossRefPubMedPubMedCentral Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ, et al. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep. 2020;10:12641.CrossRefPubMedPubMedCentral
Metadaten
Titel
Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review
verfasst von
Wataru Kitamura
Hiroki Kobayashi
Minori Noda
Akiko Iseki
Yumi Sato
Yoshinobu Maeda
Shoichi Kuyama
Publikationsdatum
15.04.2024
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03765-5

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.